New growth strategy
April 27, 2010
PHARMACEUTICAL companies
need to include emerging markets,
biologics and further cost cutting
measures if they want to stay in the
game against generics, according
to analysis firm Datamonitor.
According to reports the top 50
US pharmaceutical companies are
expected to cop a 1.3% year on
year decline in sales this year, whilst
markets outside the US are
forecasted to grow by 2.4% with
emerging markets billed to
experience an average growth rate
of 12%.
“International pharmaceutical
companies are quickly penetrating
these markets through acquisitions
of domestic generics and
manufacturing companies, which
accounted for 58% of merger and
acquisition deals in 2008 and
2009. However, our data infers that
pharma players are not fully
exploiting the growth potential and
sales opportunities provided by
these markets” said Alistair Sinclair,
head of strategic healthcare
analysis at Datamonitor.
Datamonitor also suggested that
consumer need for injectable
biologic therapies for secondary
care conditions will, in the
comming years, drive sales in major
pharma markets.
The above article was sent to subscribers in Pharmacy Daily's issue from 27 Apr 10To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Apr 10
